TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33673568

Group type: EXPERIMENTAL
Intervention: fortified sachet (vitamin D and calcium) and powdered milk plus periodontal therapy during pregnancy (early PT) (n = 17)
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo sachet and powdered milk plus early PT (n = 15)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: fortified sachet and powdered milk plus late PT (after delivery) (n = 19)
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo sachet and powdered milk plus late PT (n = 18)
Number of subjects: 69
Study: 32111770

Group type: COMPARATOR
Intervention: TACE (chemoembolization with irinotecan)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TACE-B (chemoembolization with irinotecan followed by bevacizumab)
Number of subjects: 30
Study: 33836382

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35585153

Group type: COMPARATOR
Intervention: A: no further interventions
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: E: MEM + NFS + TE
Number of subjects: 1209
Study: 32640286

Group type: EXPERIMENTAL
Intervention: 3 months of meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 36057652

Group type: EXPERIMENTAL
Intervention: Porcine-derived collagen matrix (PDCM) using modified coronally advanced tunnel (MCAT) technique
Number of subjects: 28

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG) using modified coronally advanced tunnel (MCAT) technique
Number of subjects: 28
Study: 34690787

Group type: EXPERIMENTAL
Intervention: OV101 5 mg QD (n = 8)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: OV101 5 mg BID (n = 8)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: OV101 5 mg TID (n = 7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: OV101 (all doses)
Number of subjects: 23
Study: 35400537

Group type: EXPERIMENTAL
Intervention: aboBoNT‐A 600 U
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: aboBoNT‐A 800 U
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: aboBoNT‐A 600 U and 800 U
Number of subjects: 485
Study: 36123073

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34875669

Group type: EXPERIMENTAL
Intervention: 6-session group-based program based on behavioural principles
Number of subjects: 240

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 240
Study: 33635903

Group type: EXPERIMENTAL
Intervention: Lifting unknown weights
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lifting unknown lightweights
Number of subjects: 10
Study: 32545478

Group type: EXPERIMENTAL
Intervention: 10 g of cocoa-rich chocolate (99% cocoa) daily for six months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 35929990

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX ± bevacizumab
Number of subjects: 442

Group type: COMPARATOR
Intervention: FOLFOX ± bevacizumab (Control)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C plus FOLFOX ± bevacizumab
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C plus chemotherapy
Number of subjects: 442

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 442
Study: 32274554

Group type: EXPERIMENTAL
Intervention: BMI+WHR- PGS
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: WHRonly+ PGS with average-protein diet
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: WHRonly+ PGS with high-protein diet
Number of subjects: 692
Study: 32631387

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupuncture stimulation (TEAS) at L14 and PC6, ST36 and ST37.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Sham group receiving pseudo-TEAS at sham acupoints.
Number of subjects: 280
Study: 35560696

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 464

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 464
Study: 33208593

Group type: EXPERIMENTAL
Intervention: Higher CysC concentration (≥0.78mg/L) in patients with higher hsCRP concentrations (≥4.8ng/mL)
Number of subjects: 3474

Group type: EXPERIMENTAL
Intervention: CysC
Number of subjects: 3474
Study: 32025848

Group type: EXPERIMENTAL
Intervention: KRM-20 combined with docetaxel and dexamethasone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo with docetaxel and dexamethasone
Number of subjects: 51
Study: 36251874

Group type: EXPERIMENTAL
Intervention: Babble Boot Camp (BBC)
Number of subjects: 16
Study: 33287642

Group type: EXPERIMENTAL
Intervention: Moderate observational caffeine intake from coffee (121 to 180 mg/day)
Number of subjects: 407072

Group type: EXPERIMENTAL
Intervention: Moderate observational caffeine intake from coffee (301 to 360 mg/day)
Number of subjects: 407072

Group type: COMPARATOR
Intervention: Genetically determined caffeine intake
Number of subjects: 407072
Study: 36419020

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 2 months
Number of subjects: 461

Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 461
Study: 33831589

Group type: EXPERIMENTAL
Intervention: Parenteral opioids as labor analgesia
Number of subjects: 1404
Study: 32802108

Group type: EXPERIMENTAL
Intervention: Glycyrrhiza glabra syrup (5 cc, two times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg tablets every 8 hours)
Number of subjects: 60
Study: 36107549

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus anterior plane block (SAPB) with 20 mL of 0.25% bupivacaine + general anesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: General anesthesia only (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus anterior plane block (SAPB)
Number of subjects: 44
Study: 34016158

Group type: EXPERIMENTAL
Intervention: Financial incentives contingent on low alcohol use
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Financial incentives contingent on high adherence to INH
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Escalating financial incentives for both decreasing alcohol use and increasing adherence to INH
Number of subjects: 680

Group type: COMPARATOR
Intervention: No incentives (control)
Number of subjects: 680
Study: 32723669

Group type: EXPERIMENTAL
Intervention: Grade +IV inferior shoulder mobilization, 3 sets, 60 seconds
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 22
Study: 36272898

Group type: EXPERIMENTAL
Intervention: HD-tIPNS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 33772851

Group type: EXPERIMENTAL
Intervention: Cathodal trans-spinal direct current stimulation (tsDCS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Anodal trans-spinal direct current stimulation (tsDCS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham trans-spinal direct current stimulation (tsDCS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both active tsDCS conditions
Number of subjects: 16
Study: 32580914

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the right DLPFC (10 Hz; 110% resting motor threshold; 60 trains with 50 pulses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-frequency rTMS over the left DLPFC (10 Hz; 110% resting motor threshold; 60 trains with 50 pulses)
Number of subjects: 19
Study: 34749410

Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Air Tamponade
Number of subjects: 96
Study: 36471301

Group type: EXPERIMENTAL
Intervention: Virtual simulation system training (Group V)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Jaw simulation model training (Group J)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Jaw model training followed by virtual system training (Group J-V)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Virtual system followed by jaw model training (Group V-J)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Questionnaire survey results
Number of subjects: 19
Study: 32875933

Group type: EXPERIMENTAL
Intervention: Matcha green tea powder (3x1 gram capsules per day for three weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 33428281

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg subcutaneous injections at weeks 0, 4, and 16
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fumaric acid esters (FAEs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 120
Study: 32610971

Group type: EXPERIMENTAL
Intervention: Formation of the parent C4F7N‐ anion at energies close to 0 eV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical evaporation of the F‐atom leading to the defluorinated anion C4F6N‐
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissociative electron attachment leading to several resonances and fragments
Number of subjects: 0
Study: 35584738

Group type: EXPERIMENTAL
Intervention: Exergaming (EXE)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Balance (BAL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 70
Study: 33241266

Group type: EXPERIMENTAL
Intervention: Nevirapine with rifapentine/isoniazid
Number of subjects: 78
Study: 32112738

Group type: EXPERIMENTAL
Intervention: Camrelizumab 3 mg/kg intravenously every 2 or 3 weeks
Number of subjects: 217
Study: 35830342

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Radical Cystectomy
Number of subjects: 0
Study: 34992667

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.02 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol 1.5 mg/kg
Number of subjects: 60
Study: 32554688

Group type: EXPERIMENTAL
Intervention: Multiple risk behaviour intervention (individual sessions, group sessions, communitarian activities, SMS reception)
Number of subjects: 3067

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3067
Study: 32439957

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 86

Group type: COMPARATOR
Intervention: IV indomethacin
Number of subjects: 86
Study: 32933867

Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination (EDE) original 4 subscales
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination (EDE) alternative brief 3 subscales
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bariatric loss-of-control eating episodes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bariatric overeating episodes
Number of subjects: 20
Study: 35098674

Group type: EXPERIMENTAL
Intervention: LCL161 monotherapy (1200 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LCL161 plus paclitaxel (80 mg/m2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: LCL161 monotherapy
Number of subjects: 9
Study: 32563598

Group type: EXPERIMENTAL
Intervention: Post-discharge oral nutritional supplements (ONS) with dietary advice
Number of subjects: 353

Group type: COMPARATOR
Intervention: Dietary advice alone (control)
Number of subjects: 353
Study: 32384415

Group type: EXPERIMENTAL
Intervention: Conscious thought (CT) for 2 minutes
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Unconscious thought (UT) for 2 minutes
Number of subjects: 121

Group type: COMPARATOR
Intervention: Immediate decision making
Number of subjects: 121
Study: 34494355

Group type: EXPERIMENTAL
Intervention: PMI defined by SYNTAX definition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: PMI defined by 4th UDMI definition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: PMI defined by ISCHEMIA definition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: PMI defined by SCAI definition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: PMI defined by EXCEL definition
Number of subjects: 1300
Study: 36143921

Group type: COMPARATOR
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite (NaOCl)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17% ethylenediaminetetraacetate acid (EDTA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (PVI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CNT)
Number of subjects: 100
Study: 33041014

Group type: EXPERIMENTAL
Intervention: Automated closed-loop vasopressor (CLV) controller
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual adjustment of norepinephrine infusion (Control)
Number of subjects: 30
Study: 33205662

Group type: EXPERIMENTAL
Intervention: Durable Polymer Drug-Eluting Stent (DP-DES)
Number of subjects: 3413

Group type: COMPARATOR
Intervention: Biodegradable Polymer Drug-Eluting Stent (BP-DES)
Number of subjects: 3413
Study: 32100888

Group type: EXPERIMENTAL
Intervention: Proactive relational aggression
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Reactive relational aggression
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Proactive physical aggression
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Reactive physical aggression
Number of subjects: 421
Study: 33724919

Group type: EXPERIMENTAL
Intervention: AI-based sentiment analysis of social media posts
Number of subjects: 300000
Study: 32002556

Group type: EXPERIMENTAL
Intervention: High-dose radiation (64.8 Gy in 36 fractions)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Low-dose radiation (50.4 Gy in 28 fractions)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Normal MMSE at baseline
Number of subjects: 203
Study: 33012596

Group type: EXPERIMENTAL
Intervention: TIVA with PSI monitoring (group P-PSI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TIVA without PSI monitoring (group P)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Desflurane with PSI monitoring (group D-PSI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Desflurane without PSI monitoring (group D)
Number of subjects: 120
Study: 33138837

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (HT)
Number of subjects: 6
Study: 36164038

Group type: EXPERIMENTAL
Intervention: R-CHOP + tafasitamab (12 mg/kg intravenously, Days 1, 8, and 15) + LEN (25 mg orally, Days 1-10)
Number of subjects: 880

Group type: COMPARATOR
Intervention: R-CHOP + tafasitamab + LEN placebos
Number of subjects: 880
Study: 34428259

Group type: EXPERIMENTAL
Intervention: Peer support programs
Number of subjects: 22
Study: 35365180

Group type: EXPERIMENTAL
Intervention: NIPP approach (nutrition education and SBC)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: NIPP+ approach (NIPP + agricultural inputs, training, and tools)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study: 35939577

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D3 (2000 IU per day)
Number of subjects: 25871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25871
Study: 32394049

Group type: EXPERIMENTAL
Intervention: KiVa antibullying program
Number of subjects: 4383

Group type: EXPERIMENTAL
Intervention: KiVa+ (KiVa with additional network feedback to teachers)
Number of subjects: 4383

Group type: COMPARATOR
Intervention: Control condition (waiting list, care as usual)
Number of subjects: 4383
Study: 35594968

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP) program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 33035731

Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 725

Group type: COMPARATOR
Intervention: Usual Care Control (UCC)
Number of subjects: 725
Study: 33792210

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (oral hygiene instructions, scaling and root planing)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions only)
Number of subjects: 82
Study: 32289180

Group type: EXPERIMENTAL
Intervention: Fatty liver (FL)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Nonalcoholic fatty liver disease (NAFLD)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Risk factors for FL
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Risk factors for NAFLD
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: NASH liver-related deaths
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Alcohol-related liver disease mortality
Number of subjects: 834
Study: 33580651

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Health and wellness control intervention
Number of subjects: 148
Study: 32531263

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study: 33867495

Group type: EXPERIMENTAL
Intervention: 3D images of real rotating objects using close-range photogrammetry (experimental group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional 2D images (control group)
Number of subjects: 77
Study: 34006176

Group type: EXPERIMENTAL
Intervention: Motivational interviewing supplemental to a standard 6-week CR program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (standard 6-week CR program)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 110
Study: 32687451

Group type: EXPERIMENTAL
Intervention: RVD (lenalidomide, bortezomib, and dexamethasone)
Number of subjects: 183
Study: 35565084

Group type: EXPERIMENTAL
Intervention: Telerehabilitation App guided core-stability exercises (CSE) combined with conventional physiotherapy
Number of subjects: 30
Study: 33245453

Group type: EXPERIMENTAL
Intervention: Pestalotiopsis spp. isolates (6 selected for pathogenicity tests)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-Pestalotiopsis isolates
Number of subjects: 120
Study: 34758661

Group type: EXPERIMENTAL
Intervention: Indoor running on a treadmill with static video capture
Number of subjects: 32

Group type: COMPARATOR
Intervention: Outdoor running segments obtained via drone on an outdoor track
Number of subjects: 32
Study: 32450904

Group type: EXPERIMENTAL
Intervention: CSR blogshots
Number of subjects: 238

Group type: COMPARATOR
Intervention: CSR plain language summaries (PLSs)
Number of subjects: 238
Study: 35192656

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 168

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 168
Study: 33455019

Group type: EXPERIMENTAL
Intervention: Boston Carpal Tunnel Questionnaire (BCTQ) - Symptom Severity Subscale (SSS)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Boston Carpal Tunnel Questionnaire (BCTQ) - Functional Status Subscale (FSS)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall BCTQ scoring
Number of subjects: 600
Study: 34015014

Group type: EXPERIMENTAL
Intervention: TaurolockU (taurolidine heparin locks twice a week combined with taurolidine urokinase locks once a week)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (taurolidine heparin locks thrice weekly)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: TaurolockU
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 34172071

Group type: EXPERIMENTAL
Intervention: Inspiratory and expiratory respiratory muscle training (IEMT) for 8 weeks, consisting of 5 sets of 10 repetitions, three times a day, with increasing training loads weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham-IEMT protocol
Number of subjects: 50
Study: 35998673

Group type: EXPERIMENTAL
Intervention: Minimal water exchange (MWE)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Left water exchange (LWE)
Number of subjects: 226
Study: 33167972

Group type: EXPERIMENTAL
Intervention: 3D high definition
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2D high definition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3D system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2D and 3D systems
Number of subjects: 50
Study: 34875694

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 756
Study: 32708555

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg−1) for 4 days, acute intake on day 5
Number of subjects: 14
Study: 34739431

Group type: EXPERIMENTAL
Intervention: Bedside Entertainment and Relaxation Theater (BERT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 66
Study: 32513307

Group type: EXPERIMENTAL
Intervention: Structured decision support (nurse-led decision coaching and evidence-based patient decision aid) alongside usual care
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 398
Study: 35486411

Group type: EXPERIMENTAL
Intervention: Contextualized DDI management
Number of subjects: 3772

Group type: COMPARATOR
Intervention: Basic DDI management
Number of subjects: 3772
Study: 33484864

Group type: EXPERIMENTAL
Intervention: Omadacycline 100 mg intravenously (every 12 h for two doses, then every 24 h) with optional transition to 300 mg orally after 3 days
Number of subjects: 660

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg intravenously (every 24 h) with optional transition to 400 mg orally after 3 days
Number of subjects: 660
Study: 32466746

Group type: EXPERIMENTAL
Intervention: Regional anesthesia (infraclavicular nerve block)
Number of subjects: 52

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 52
Study: 34690334

Group type: EXPERIMENTAL
Intervention: Bergamot essential oil aroma intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pure water aroma (control)
Number of subjects: 60
Study: 33343034

Group type: EXPERIMENTAL
Intervention: Pulsatile pump flow
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonpulsatile pump flow
Number of subjects: 52
Study: 36464891

Group type: EXPERIMENTAL
Intervention: Head box group
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (without head box)
Number of subjects: 190